The pharmacy industry is under increasing scrutiny from all angles. Whether at the legislative or agency level, Washington as well as many states seem intent on addressing perceived issues surrounding drug pricing, reimbursement, and program integrity. For these reasons, Mintz Levin and ML Strategies brought together stakeholders and thought leaders from across the industry to share knowledge and insight on this rapidly shifting landscape at the 2016 Mintz Levin/ML Strategies Pharmacy Industry Summit in Washington, DC on May 10.
As drug pricing was a common thread throughout the Summit, those in the pharmacy industry may be interested in a recent ML Strategies White Paper “Transparency in Drug Pricing: Issues to Consider from the Research Lab to the Consumer.”
Here’s some of the #MLPharma Twitter buzz:
— Dorothy Hoffman (@dorothyhoffman) May 10, 2016
— Rodney Whitlock (@RodneyMLS) May 10, 2016
— ML Strategies (@MLStrategies) May 10, 2016
The future holds a lot of potential for tying drug pricing to value but there is still a lot of work to be done #MLPharma
— ThinkAnthem (@ThinkAnthem) May 10, 2016
— Mo Cowan (@mocowan) May 10, 2016
— Mintz Levin (@MintzLevin) May 10, 2016
— Bianca Desai (@Bianca_MPH) May 10, 2016
— Eli (@eligreenspan) May 10, 2016
See you next year in DC!